Niu Shaoxi, Ao Liyan, Gao Yu, Zhou Fangjian, He Wang, Tao Jin, Guo Shengjie, Wang Baojun, Ai Xing, Li Hongzhao, Ma Xin, Zhang Xuepei, Huang Jian, Zhang Xu
Department of Urology, Third Medical Centre, Chinese PLA General Hospital, Beijing 100039, China.
Graduate School of Chinese PLA Medical School, Beijing, China.
Eur Urol Open Sci. 2024 Apr 25;64:2-8. doi: 10.1016/j.euros.2024.02.017. eCollection 2024 Jun.
Robot-assisted radical prostatectomy (RARP) is widely used because of the many advantages of a robotic approach. The da Vinci Si robot is one of the most commonly used surgical robot systems, but it may be associated with higher costs owing to the use of consumable surgical supplies. Our aim was to conduct a preliminary investigation of the capability of the MP1000 system for RARP.
In this prospective, multicentre, single-blinded study, we randomly assigned 42 patients scheduled to undergo RARP between April and September 2021 to a da Vinci Si group (control) or an MP1000 group (intervention). Patients underwent RARP performed using the assigned robotic system and were followed up at 3-mo intervals. The primary outcome was the rate of conversion to open/laparoscopic surgery. Secondary outcomes were installation and operation times, intraoperative blood loss, postoperative surgical margin status, hospital stay, incontinence, complications, safety indicators, and surgeon ergonomics.
All procedures were successfully completed without conversion to open/laparascopic surgery or major complications. Secondary outcomes, including oncological and ergonomic indicators, did not differ significantly between the groups over the study period. One patient in the control group experienced dysuria (Clavien-Dindo grade 3). No patients had incontinence at 3 mo. A limitation of the study is the small sample size.
RARP with the MP1000 system is feasible, safe, and effective in the management of localised prostate cancer.
We assessed the effectiveness and safety of the new MP1000 robot system for robot-assisted removal of the prostate in comparison to the da Vinci Si robot. We found no difference in effectiveness or safety among 42 patients with prostate cancer who were assigned randomly to one of the two systems. We conclude that the MP1000 is a suitable robot for this surgery.
机器人辅助根治性前列腺切除术(RARP)因机器人手术方式具有诸多优势而被广泛应用。达芬奇Si机器人是最常用的手术机器人系统之一,但由于使用一次性手术耗材,其成本可能较高。我们的目的是对MP1000系统用于RARP的能力进行初步研究。
在这项前瞻性、多中心、单盲研究中,我们将2021年4月至9月计划接受RARP的42例患者随机分为达芬奇Si组(对照组)或MP1000组(干预组)。患者使用指定的机器人系统进行RARP,并每3个月进行一次随访。主要结局是转为开放/腹腔镜手术的比例。次要结局包括安装和手术时间、术中失血量、术后手术切缘状态、住院时间、尿失禁、并发症、安全指标和外科医生人体工程学指标。
所有手术均成功完成,未转为开放/腹腔镜手术或出现重大并发症。在研究期间,两组之间的次要结局,包括肿瘤学和人体工程学指标,差异均无统计学意义。对照组有1例患者出现排尿困难(Clavien-Dindo 3级)。3个月时无患者出现尿失禁。本研究的一个局限性是样本量小。
MP1000系统用于RARP治疗局限性前列腺癌是可行、安全且有效的。
我们评估了新型MP1000机器人系统与达芬奇Si机器人相比在机器人辅助前列腺切除术中的有效性和安全性。我们发现,随机分配到这两种系统之一的42例前列腺癌患者在有效性或安全性方面没有差异。我们得出结论,MP1000是适合该手术的机器人。